Table 2 Changes of clinical endpoints from baseline to week 24
Endpoint | Placebo (n = 82) | Neflamapimod (n = 78) | Difference in change (95% CI) | P value |
|---|---|---|---|---|
HVLT-R combined Z-score Total and Delayed Recall | −0.13 (−0.27, 0.01) | −0.17 (−0.38, 0.05) | −0.03 (-0.23, 0.16) | NS |
WMS Immediate & Delayed Recall | 16.6 (11.1, 22.1) | 16.0 (10.5, 21.5) | -0.6 (−6.0, 4.8)) | NS |
CDR-SB | 1.0 (0.5, 1.5) | 1.1 (0.6, 1.7) | 0.1 (−0.4, 0.6) | NS |
MMSE | −0.5 (−1.3, 0.3) | −0.8 (−1.7, 0.1) | −0.3 (−1.0, 0.5) | NS |